Mechanism and clinical efficacy of peripheral blood alive cell treatment on androgenic alopecia  

作　　者：Zigang Zhao Xin Zhang Xiaoyan Qu Yaguang Zhou Shui Yu Qinyi Wang Qian Zhang 

机构地区：[1]Department of Dermatology,Hainan Hospital of PLA General Hospital,Sanya,Hainan 572013,China [2]Department of Dermatology,The First Medical Center of PLA General Hospital,Beijing 110000,China [3]Department of Product Research&Development,AVIC(Ningxia)Biology Co.,Ltd.,Yinchuan,Ningxia 750011,China [4]CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China.

出　　处：《Chinese Medical Journal》2024年第20期2507-2508,共2页中华医学杂志(英文版)

基　　金：supported by grants from the Natural Science Foundation of Hainan Province(No.820MS123);the Guangdong Enterprise Joint Fund(No.2022A1515220137);the Shenzhen Science and Technology Innovation Committee(No.JCYJ20220530141615035).

摘　　要：To the Editor:Androgenic alopecia(AGA)is a common chronic hair loss disorder that usually begins in adolescence,with hair follicle miniaturization.[1]Clinical manifestations include reduced hair diameter and volume,potentially leading to baldness.AGA,characterized by progressive hair loss,can affect both sexes.Inflammation around the hair follicle,stress,emotional tension,and poor lifestyle and eating habits can further aggravate the symptoms of AGA.[2]Currently,minoxidil and finasteride(FNS)are the only drug therapies specifically approved for AGA by the FDA.[3]However,these two drugs have obvious side effects and poor patient compliance,so it is urgent to find a safe and effective clinical treatment method for AGA.

关 键 词：CLINICAL DRUGS TREATMENT 

分 类 号：R73[医药卫生—肿瘤]